WHAT IS CLAIMED IS:

1. A system comprising capreomycin and a device for introducing said capreomycin into gases for inhalation by a person in need thereof.

2. A system of claim 1, wherein said capreomycin is introduced into said gases as a solution, a suspension, a powder, or a spray.

3. A system of claim 1, wherein said device is a nebulizer, a metered dose inhaler, or a dry powder inhaler.

4. A system of claim 3, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

5. A system of claim 1, wherein said capreomycin is introduced into said gases in an average particle size of between 1 and 10 microns.

6. A system of claim 5, wherein said capreomycin has an average particle size of between 2 and 6 microns.

7. A system of claim 5, wherein said capreomycin has an average particle size of about 3 to about 5 microns.

8. A system of claim 1, wherein said capreomycin is provided as a powder.

9. A system of claim 8, wherein said capreomycin is introduced into said gases in an average particle size of between 1 and 10 microns.

10. A system of claim 9, wherein said capreomycin has an average particle size of about 3 to about 5 microns.

11. A formulation of capreomycin suitable for aerosol administration.

12. A formulation of capreomycin of claim 11, wherein said capreomycin has an average particle size between 1 and 10 microns.

13. A formulation of capreomycin of claim 12, wherein said capreomycin is complexed or associated with a polysaccharide.

14. A method of inhibiting the growth of *Mycobacterium tuberculosis* ("MTB"), said method comprising introducing capreomycin into gases to be inhaled by a patient in need thereof.

15. A method of claim 14, wherein said capreomycin is introduced into said gases as a solution, a suspension, a powder, or a spray.

16. A method of claim 14, wherein said capreomycin introduced into said gases in an average particle size of between 1 and 10 microns.

17. A method of claim 14, wherein said capreomycin is complexed or associated with a polysaccharide.

18. A method of claim 14, wherein said capreomycin is introduced into said gases by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

19. A method of claim 18, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

20. A method of inhibiting the growth of *Mycobacterium tuberculosis* ("MTB") in a patient, said method comprising administering to a lung of said patient aerosolized capreomycin, wherein said capreomycin inhibits the growth of MTB in said patient.

21. A method of claim 20, wherein said capreomycin is administered to said lung as a solution, a suspension, a powder, or a spray.

22. A method of claim 20, wherein said capreomycin is administered to said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

23. A method of claim 22, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

24. A method of reducing infectivity of a person infected with *Mycobacterium tuberculosis* ("MTB"), said method comprising administering to the lung of said person aerosolized capreomycin, wherein said capreomycin reduces the infectivity of said person.

25. A method of claim 24, wherein said capreomycin is administered to said lung as a solution, a suspension, a powder, or a spray.

26. A method of claim 24, wherein said capreomycin is administered to said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

27. A method of claim 26, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

28. A use of capreomycin for manufacture of a medicament for aerosolized administration to a lung as a solution, a suspension, a powder, or a spray.

29. A use of claim 28, wherein said medicament is suitable for delivery to said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

30. A formulation of lyophilized capreomycin having an average particle size of from about 1 to about 10 microns.